Toleranzia AB (publ) (STO:TOL)

Market Cap	131.69M
Revenue (ttm)	31.52M
Net Income (ttm)	-11.94M
Shares Out	270.96M
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,513,661
Average Volume	1,074,509
Open	0.4860
Previous Close	0.4860
Day's Range	0.4830 - 0.4920
52-Week Range	0.2700 - 0.7240
Beta	1.00
RSI	59.47
Earnings Date	Aug 29, 2025

About Toleranzia AB

Toleranzia AB (publ), a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate in clinical trial for treating myasthenia gravis, an autoimmune nerve and muscle disease. The company also develops TOL3 drug candidate for the treatment of ANCA vasculitis, an autoimmune blood vessel disease. In addition, it is also developing tolerogens technology, a treatment method that creates disease-specific tolerance in the immune system for treating var...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2011
• Employees: 10
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: TOL

Financial Performance

In 2024, Toleranzia AB's revenue was 31.07 million, a decrease of -38.98% compared to the previous year's 50.92 million. Losses were -9.44 million, 26.5% more than in 2023.